AI BriefingBristol Myers Squibb (BMS) Builds State-of-the-Art Life Sciences AI Factory Based on NVIDIA Vera Rubin
Key point
Bristol Myers Squibb (BMS) is significantly expanding its AI infrastructure by adopting NVIDIA DGX SuperPOD to accelerate drug discovery.
Details
Global pharmaceutical company Bristol Myers Squibb (BMS) is introducing its second NVIDIA DGX SuperPOD, building the most powerful AI cluster in the life sciences field. The system consists of 8 DGX Vera Rubin NVL72 systems, and is notable for improving performance per watt by up to 10x compared to existing infrastructure.
Through this infrastructure expansion, BMS provides an environment where all researchers can use computing resources without restriction. Researchers utilize an integrated AI platform including the NVIDIA BioNeMo Agent Toolkit to perform the following tasks.
- Prediction and model training across the entire drug discovery pipeline
- Driving agentic workflows
- Large-scale molecular structure prediction and foundation model building
BMS is already achieving tangible results using AI, such as shortening target identification time and expanding its CELMoD compound library for cancer treatment. In addition, through its 'Predict First' methodology, it predicts the properties of molecules before experiments, increasing the probability of experimental success and minimizing resource waste.
This summary was generated automatically by AI. Check the original for the author's claims and context. Copyright belongs to the original author.
Our guide explains how the AI works. Report summary errors, attribution issues, or removal requests via Contact.
Related
Stanford and NVIDIA Release 'Contrastive Language Model' CLM with 9x Faster Inference